Powering the future of genetic medicines with precision delivery
ReCode is developing therapeutics for genetically defined diseases with no existing treatment options including primary ciliary dyskinesia and cystic fibrosis.
Targeted Delivery TechnologyFirst platform to enable highly targeted delivery of genetic medicines to organs, tissues and cells beyond the liver
Precision Genetic MedicinesPipeline of rare disease therapeutics using optimized mRNA and gene correction with redosing capability
Versatile Cargo & Delivery PotentialUnique platform properties enable the packaging and delivery of a wide range of genetic medicine cargoes via multiple routes of administration
ReCode’s Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platformThe SORT LNP platform is a first-in-class modular technology that goes beyond the lipid nanoparticle delivery systems used in the mRNA COVID-19 vaccines. Our platform is engineered to deliver the right genetic therapeutic to the right organs and tissues with the optimal mode of administration.
A New Era of Possibility for Genetic Medicines
ReCode’s technology has the potential to transcend the limitations of current genetic medicine delivery systems so that people with rare diseases may fully benefit from disease-modifying, corrective therapeutics.
ReCode Your Future
We’re seeking teammates who see unlimited potential in themselves and the future of genetic medicine.